Invivyd Trial Design Signals Scrutiny of mRNA Vaccine Safety

Event summary

  • Invivyd is conducting a Phase 3 LIBERTY trial comparing its VYD2311 antibody to mRNA COVID vaccines, and evaluating co-administration.
  • The FDA has requested specific monitoring for adverse events (AESIs) like myocarditis/pericarditis in the LIBERTY trial due to risks associated with mRNA vaccines – a request not made in prior Invivyd trials.
  • The LIBERTY trial is designed to complement the ongoing DECLARATION trial, which is expected to release top-line data mid-2026.
  • VYD2311 leverages the same antibody backbone as pemivibart, an investigational mAb with existing Emergency Use Authorization.

The big picture

Invivyd's LIBERTY trial underscores a growing divergence in approaches to COVID-19 prevention, with a focus on antibody-mediated prophylaxis as a potential alternative to mRNA vaccines. The FDA's request for specific AESI monitoring highlights a heightened awareness of vaccine safety concerns, potentially driven by public perception and recent CDC surveys. This trial’s outcome could significantly influence the future of COVID-19 prevention strategies and the competitive landscape for Invivyd.

What we're watching

Regulatory Scrutiny
The FDA’s heightened scrutiny of AESIs in the LIBERTY trial suggests a potential shift in the regulatory landscape for antibody-based COVID prevention, which could impact future trial designs and approval pathways.
Clinical Adoption
Whether patient concerns about mRNA vaccine side effects, highlighted by the CDC survey, will meaningfully impact adoption of existing mRNA vaccines and create a sustained market opportunity for alternative prophylactic approaches like VYD2311 remains to be seen.
Trial Execution
The success of the LIBERTY trial hinges on timely enrollment and data collection, particularly given the FDA’s specific monitoring requests; any delays or complications could significantly impact Invivyd’s timeline for VYD2311 approval.